Researchers at the University of Edinburgh have made a groundbreaking discovery in the fight against Crohn's disease, identifying clusters of immune cells as a key trigger for the development of debilitating bowel scarring. This finding, detailed in a recent study published in the Journal of Pathology, opens new avenues for targeted therapies that could prevent or slow fibrosis, a complication affecting up to one in five patients with this chronic inflammatory bowel disease (IBD).

The study, led by a multidisciplinary team from the Institute of Genetics and Cancer, highlights how these immune cell clusters—termed Crohn's lymphoid aggregates (CLAs)—interact with endothelial cells and collagen-producing myofibroblasts to drive excessive scar tissue formation, particularly in the submucosa layer of the ileum. This ileal fibrosis often leads to strictures, narrowing the intestine and necessitating surgery.

Understanding Crohn's Disease and Its Fibrotic Complications

Crohn's disease is a lifelong condition characterized by persistent inflammation anywhere along the gastrointestinal tract, from mouth to anus, though it most commonly affects the terminal ileum and colon. Unlike ulcerative colitis, another form of IBD confined to the colon, Crohn's involves transmural inflammation, penetrating all layers of the bowel wall. In the United Kingdom, IBD impacts approximately 300,000 people, with Crohn's accounting for roughly half of cases. Prevalence has been rising, with one study noting rates as high as one in 125 in Edinburgh.

While anti-inflammatory treatments like biologics (e.g., anti-TNF agents such as infliximab) and immunomodulators have reduced flare-ups, they do little to halt fibrosis. Over time, unchecked inflammation triggers fibroblasts to deposit excess collagen, thickening the bowel wall. This fibrosis complicates up to 50% of cases, with 20-25% of patients requiring surgery within 10 years of diagnosis, despite declining rates due to better medical management. Surgery, often an ileocecal resection, carries risks of recurrence, with endoscopic evidence in 70-90% of patients within a year.

Patients like Maureen Dalgleish, a 65-year-old retired teacher from Edinburgh diagnosed in 1988, have endured multiple surgeries (2001, 2006, 2013, 2025) due to recurrent strictures. Her story underscores the human toll: severe pain, liquid diets, and a life 'on hold,' yet she donated tissue to advance research.

University of Edinburgh's Pivotal Role in IBD Research

The University of Edinburgh has long been at the forefront of gastrointestinal research, particularly through its Institute of Genetics and Cancer and Centre for Inflammation Research. Home to groups like Charlie Lees' Transformative IBD Medicine team, the institution builds data-driven tools for personalized therapy and hosts cohorts like the MUSIC IBD study for patient insights. Previous contributions include genetic clues to NOD2 mutations, mitochondrial roles in flares, and predictive models using stool tests and diet.

This latest project exemplifies collaborative excellence, involving pathologists, gastroenterologists, bioinformaticians from Heriot-Watt University, Earlham Institute, and Sanger Institute. Funded by the Leona M. and Harry B. Helmsley Charitable Trust, it spans six years of rigorous analysis.

Methodology: From Tissue Analysis to Single-Cell Insights

The team examined archived and fresh resection samples from fibrostenosing Crohn's disease (FSCD) patients, focusing on ileal layers: mucosa, muscularis mucosae, submucosa, muscularis propria, and serosa. Traditional histopathology quantified fibrosis via collagen staining and immune infiltration via CD45+ cells.

Advanced single-cell RNA sequencing (scRNA-seq) profiled thousands of cells, revealing transcriptional states. Computational tools mapped ligand-receptor interactions, such as GAS6-MER/TYRO3 between endothelium and myofibroblasts, SELL-SELLPGL between lymphocytes and endothelium.

• Archived samples showed transmural fibrosis expansion, maximal in submucosa.
• Fresh scRNA-seq validated increased myeloid cells, lymphocytes, endothelial clusters.
• CLAs colocalized with endothelial clusters (density >10,000/mm²), correlating strongly with collagen (r=0.84).

This dual validation—pathology and transcriptomics—ensures robustness.

Photo by Finde Zukunft on Unsplash

Key Findings: Immune-Endothelial Axis in Fibrosis

Central discovery: CLAs, rich in B and T lymphocytes, recruit endothelial cells forming perivascular structures. These endothelial clusters signal myofibroblasts via multiple pathways, promoting collagen deposition. Submucosa emerges as fibrosis epicenter, with serosa secondary. No granulomas in 87% cases, emphasizing lymphoid over granulomatous pathology.

scRNA-seq clusters: expanded fibroblasts (matrix-producing), inflammatory macrophages, activated endothelium expressing pro-fibrotic ligands. This 'immune-endothelial-myofibroblast' triad redefines FSCD pathogenesis.

Spotlight on Lead Researchers

Dr. Michael Glinka, postdoctoral fellow, spearheaded integration of pathology and genomics: "Our findings highlight previously unrecognised interactions... providing new therapeutic targets."

Dr. Shahida Din, NHS Lothian consultant and honorary lecturer, bridges clinic and lab: "Fibrosis remains challenging... could guide therapies preventing scarring." Prof. Mark Arends heads pathology, leveraging decades in GI oncology.

Catherine Winsor of Crohn's & Colitis UK hails it as explaining 'scarring drivers,' offering hope beyond inflammation control.

Treatment Implications and Emerging Anti-Fibrotics

Current arsenal—steroids, 5-ASAs, biologics—targets inflammation, not fibrosis. Surgery remains endpoint for strictures. This study nominates CLA-endothelial signaling for inhibition: e.g., anti-ROCK inhibitors like RXC008 in trials, TL1A antagonists, or myofibroblast modulators like ontunisertib (Phase 2a positive).Read the full paper here.

Pipeline excitement: Broad Institute's gene-protective molecules, AI-designed antifibrotics. Edinburgh's prior mitochondrial work complements, eyeing non-invasive diagnostics.

• Target CLAs to disrupt nucleation.
• Inhibit endothelial signaling (SELL, GAS6).
• Monitor submucosal changes early.

Patient Perspectives and Real-World Impact

Maureen's four surgeries highlight urgency: post-op recurrence common, quality of life impaired. Advances like biologics extended her intervals, but fibrosis persists. New targets could avert her 2025 procedure, transforming prognosis for young diagnoses (peak 15-30 years).

Crohn's & Colitis UK notes 25,000 annual UK diagnoses; early intervention via PREdiCCt-like predictors vital.University press release.

Photo by Clayton Robbins on Unsplash

Future Directions and University Research Ecosystem

Edinburgh plans FATE-CD imaging for fibrosis tracking, gut organoids for drug screening. Global context: rising IBD in Asia/Africa demands scalable solutions. Uni's bioquarter fosters spinouts like IBDSENSE stool tests.

Careers abound: postdocs in genomics, clinical fellows in IBD, faculty in pathology—fueling UK's research leadership.

Broader Implications for Higher Education and Academia

This exemplifies interdisciplinary higher ed impact: clinician-scientists train future leaders, securing grants like Helmsley. Edinburgh ranks top globally in medicine, attracting talent amid post-Brexit challenges. For academics, such breakthroughs boost citations, collaborations, funding.

Stakeholders—patients, pharma, policymakers—benefit from evidence-based progress, positioning UK unis as IBD hubs.